Nuveen AMT-Free Municipal Credit Income Fund of Beneficial Interest (NVG)
Market Closed
16 Oct, 08:00 PM
NYSE NYSE Primary NASDAQ $
10. 89
+0.06
+0.554%
$
2.28B Market Cap
0.77% Div Yield
1.39M Volume
$ 10.83
Previous Close 
Want to track NVG and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291's ability to replicate efficacy in chronic tetraplegia. Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291's neural recovery over compensatory adaptation.
Seekingalpha | 3 months ago
2026 © Marketlog. All Rights Reserved.
